It was reported that the procedure was to treat a lesion in the left anterior descending (lad) and proximal left circumflex (plcx) with 90% stenosis, mild calcification and mild tortuosity.The patient's left ventricular ejection fraction (lvef) was 48%.The plcx was treated with 2.5x15mm xience alpine stent at 16 atmospheres (atms) and post dilated with 2.5x12mm nc trek balloon.The lad was treated with 2.75x38 xience alpine stent at 16 atms and post dilated with 2.75x20mm nc trek balloon at 18 atms.Post dilatation was performed per standard procedure.Timi 3 flow was achieved.There was no adverse patient effect and there was no clinically significant delay in the procedure.However, on 03/12/2024, the patient came back with chest pain and both vessels where the stents were implanted confirmed blockage on coronary artery angiography (cag).Electrocardiogram (ecg) and troponin test was performed for the chest pain.Occlusion was confirmed to be thrombosis.Patient was referred for coronary artery bypass grafting (cabg) and unknown when it will be performed.No additional information was provided.
|
The device was not returned for analysis.Lot history record (lhr) and exception reviews were performed and revealed no indication of a product quality issue.Additionally, a review of the complaint history identified no similar incidents from this lot.The reported patient effects of thrombosis and angina are listed in the xience alpine everolimus eluting coronary stent system (eifu), electronic instructions for use (eifu), as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.The additional xience alpine device(s) referenced in b5 is/are filed under separate medwatch report number(s).
|